{
  "schema": 1,
  "as_of": "2026-11-04",
  "year": 2026,
  "coverage": "Source-verified subset of the two named inputs; unresolved profile records are excluded. Announcement year is used where signing date is undisclosed.",
  "rows": [
    {
      "id": "TW2026-b60ec118c2e6",
      "announcement_date": "2026-10-05",
      "signed_date": "2026-10-05",
      "licensor_zh": "TLC-KY／台灣微脂體股份有限公司",
      "licensor_en": "TLC BioSciences Corp. / Taiwan Liposome Company",
      "licensor_ticker": "7924",
      "licensor_country": "Taiwan",
      "licensee": "Nippon Zoki Pharmaceutical Co., Ltd.",
      "licensee_country": "Japan",
      "asset": "TLC599",
      "indication": "Knee osteoarthritis pain",
      "territory": "日本",
      "upfront": null,
      "milestones_cap": null,
      "total_cap": 203000000,
      "currency": "USD",
      "royalty_text": "最高可達雙位數百分比之分級銷售權利金",
      "source_urls": [
        "https://mops.twse.com.tw/mops/#/web/t05st01",
        "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=1&step=2&seq_no=1&spoke_time=152833&spoke_date=20261005&co_id=7924&TYPEK=rotc"
      ],
      "source_date": "2026-10-05",
      "data_date": "2026-11-04",
      "origins": [
        "search_deals"
      ],
      "input_ids": [
        "PROFILE-e93c3868740072f6"
      ],
      "source_url": "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=1&step=2&seq_no=1&spoke_time=152833&spoke_date=20261005&co_id=7924&TYPEK=rotc"
    },
    {
      "id": "TW2026-d1d807f4480b",
      "announcement_date": "2026-09-16",
      "signed_date": "2026-09-16",
      "licensor_zh": "瑩碩生技",
      "licensor_en": "ANXO",
      "licensor_ticker": "6677",
      "licensor_country": "Taiwan",
      "licensee": "YS Life Science",
      "licensee_country": "South Korea",
      "asset": "益利舒持續釋放口溶錠",
      "indication": "攝護腺肥大排尿障礙",
      "territory": "韓國",
      "upfront": null,
      "milestones_cap": null,
      "total_cap": null,
      "currency": null,
      "royalty_text": null,
      "source_urls": [
        "https://www.anxo.com.tw/news/view/231"
      ],
      "source_date": "2026-09-16",
      "data_date": "2026-11-04",
      "origins": [
        "search_deals"
      ],
      "input_ids": [
        "PROFILE-4204f3a292d106e4"
      ],
      "source_url": "https://www.anxo.com.tw/news/view/231"
    },
    {
      "id": "TW2026-630b0880a1d0",
      "announcement_date": "2026-08-10",
      "signed_date": "2026-08-10",
      "licensor_zh": "順藥",
      "licensor_en": "LUMOSA",
      "licensor_ticker": "6535",
      "licensor_country": "Taiwan",
      "licensee": "安美得生醫股份有限公司",
      "licensee_country": "Taiwan",
      "asset": "LT1001（中東增補）",
      "indication": "疼痛",
      "territory": "沙烏地阿拉伯、科威特、阿拉伯聯合大公國、阿曼、卡達、巴林",
      "upfront": null,
      "milestones_cap": null,
      "total_cap": null,
      "currency": null,
      "royalty_text": null,
      "source_urls": [
        "https://mops.twse.com.tw/mops/#/web/t05st01?companyId=6535",
        "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=1&step=2&seq_no=5&spoke_time=180917&spoke_date=20260810&co_id=6535&TYPEK=otc"
      ],
      "source_date": "2026-08-10",
      "data_date": "2026-11-04",
      "origins": [
        "search_deals"
      ],
      "input_ids": [
        "PROFILE-ddcc1433195da82c"
      ],
      "source_url": "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=1&step=2&seq_no=5&spoke_time=180917&spoke_date=20260810&co_id=6535&TYPEK=otc"
    },
    {
      "id": "TW2026-059b4a660020",
      "announcement_date": "2026-06-11",
      "signed_date": null,
      "licensor_zh": "台新藥股份有限公司",
      "licensor_en": "Formosa Pharmaceuticals, Inc.",
      "licensor_ticker": "TWSE: 6838",
      "licensor_country": "Taiwan",
      "licensee": "Samil Pharmaceuticals Co., Ltd.",
      "licensee_country": "South Korea",
      "asset": "APP13007",
      "indication": "Inflammation and pain following ocular surgery",
      "territory": "Vietnam",
      "upfront": null,
      "milestones_cap": null,
      "total_cap": null,
      "currency": null,
      "royalty_text": "royalties, throughout the term of the agreement",
      "source_urls": [
        "https://www.formosapharma.com/%E5%8F%B0%E6%96%B0%E8%97%A5%E5%AE%A3%E5%B8%83%E8%88%87samil-pharmaceutical-%E7%B0%BD%E7%BD%B2%E6%8E%88%E6%AC%8A%E5%8D%94%E8%AD%B0%EF%BC%8C%E6%8E%A8%E5%8B%95%E7%9C%BC%E9%83%A8%E8%A1%93%E5%BE%8C/",
        "https://mops.twse.com.tw/mops/#/web/t05st01?companyId=6838"
      ],
      "source_date": "2026-06-11",
      "data_date": "2026-11-04",
      "origins": [
        "search_deals"
      ],
      "input_ids": [
        "TW-2026-003",
        "PROFILE-3c85cdda3cf9c43f"
      ],
      "source_url": "https://www.formosapharma.com/%E5%8F%B0%E6%96%B0%E8%97%A5%E5%AE%A3%E5%B8%83%E8%88%87samil-pharmaceutical-%E7%B0%BD%E7%BD%B2%E6%8E%88%E6%AC%8A%E5%8D%94%E8%AD%B0%EF%BC%8C%E6%8E%A8%E5%8B%95%E7%9C%BC%E9%83%A8%E8%A1%93%E5%BE%8C/"
    },
    {
      "id": "TW2026-180c403f56d2",
      "announcement_date": "2026-02-23",
      "signed_date": null,
      "licensor_zh": "台新藥股份有限公司",
      "licensor_en": "Formosa Pharmaceuticals, Inc.",
      "licensor_ticker": "TWSE: 6838",
      "licensor_country": "Taiwan",
      "licensee": "Arrotex Pharmaceuticals Pty Ltd.",
      "licensee_country": "Australia",
      "asset": "APP13007",
      "indication": "Inflammation and pain following ocular surgery",
      "territory": "Australia and New Zealand",
      "upfront": null,
      "milestones_cap": null,
      "total_cap": null,
      "currency": null,
      "royalty_text": "royalty considerations throughout the terms of the agreement",
      "source_urls": [
        "https://www.formosapharma.com/formosa-pharmaceuticals-announces-licensing-agreement-with-arrotex-for-commercialization-of-clobetasol-propionate-ophthalmic-suspension-for-the-treatment-of-inflammation-and-pain-following-ocular-sur/",
        "https://mops.twse.com.tw/mops/#/web/t05st01?companyId=6838"
      ],
      "source_date": "2026-02-23",
      "data_date": "2026-11-04",
      "origins": [
        "asia",
        "search_deals"
      ],
      "input_ids": [
        "ASIA-2026-199406b72c3a",
        "TW-2026-002",
        "PROFILE-880f9950bebc3c9f"
      ],
      "source_url": "https://www.formosapharma.com/formosa-pharmaceuticals-announces-licensing-agreement-with-arrotex-for-commercialization-of-clobetasol-propionate-ophthalmic-suspension-for-the-treatment-of-inflammation-and-pain-following-ocular-sur/"
    },
    {
      "id": "TW2026-83f1586feb50",
      "announcement_date": "2026-01-26",
      "signed_date": null,
      "licensor_zh": "太景醫藥研發控股股份有限公司",
      "licensor_en": "TaiGen Biopharmaceuticals Holdings Ltd.",
      "licensor_ticker": "TPEx:4157",
      "licensor_country": "Taiwan",
      "licensee": "Boryung Biopharma Co., Ltd.",
      "licensee_country": "South Korea",
      "asset": "TG-1000",
      "indication": "Influenza",
      "territory": "South Korea",
      "upfront": null,
      "milestones_cap": null,
      "total_cap": null,
      "currency": null,
      "royalty_text": "royalties on net sales",
      "source_urls": [
        "https://www.taigenbiotech.com/en/news/detail/226",
        "https://www.taigenbiotech.com/tw/material/detail/181"
      ],
      "source_date": "2026-01-26",
      "data_date": "2026-11-04",
      "origins": [
        "search_deals"
      ],
      "input_ids": [
        "TW-2026-005",
        "PROFILE-aaba5f961d799c53"
      ],
      "source_url": "https://www.taigenbiotech.com/en/news/detail/226"
    },
    {
      "id": "TW2026-716343ea5611",
      "announcement_date": "2026-01-12",
      "signed_date": null,
      "licensor_zh": "台新藥股份有限公司",
      "licensor_en": "Formosa Pharmaceuticals, Inc.",
      "licensor_ticker": "TWSE: 6838",
      "licensor_country": "Taiwan",
      "licensee": "Samil Pharmaceuticals Co., Ltd.",
      "licensee_country": "South Korea",
      "asset": "APP13007",
      "indication": "Inflammation and pain following ocular surgery",
      "territory": "South Korea",
      "upfront": null,
      "milestones_cap": null,
      "total_cap": null,
      "currency": null,
      "royalty_text": "royalties, throughout the term of the agreement",
      "source_urls": [
        "https://www.formosapharma.com/formosa-pharmaceuticals-announces-licensing-agreement-with-samil-pharmaceuticals-co-ltd-for-commercialization-of-clobetasol-propionate-ophthalmic-suspension-for-the-treatment-of-inflammation-and-p/",
        "https://mops.twse.com.tw/mops/#/web/t05st01?companyId=6838"
      ],
      "source_date": "2026-01-12",
      "data_date": "2026-11-04",
      "origins": [
        "search_deals"
      ],
      "input_ids": [
        "TW-2026-001",
        "PROFILE-bfc775d81c2d30d1"
      ],
      "source_url": "https://www.formosapharma.com/formosa-pharmaceuticals-announces-licensing-agreement-with-samil-pharmaceuticals-co-ltd-for-commercialization-of-clobetasol-propionate-ophthalmic-suspension-for-the-treatment-of-inflammation-and-p/"
    },
    {
      "id": "TW2026-511f8c79f916",
      "announcement_date": "2026-01-08",
      "signed_date": null,
      "licensor_zh": "逸達生物科技股份有限公司",
      "licensor_en": "Foresee Pharmaceuticals Co., Ltd. (through Foresee Pharmaceuticals USA Inc.)",
      "licensor_ticker": "TPEx: 6576",
      "licensor_country": "Taiwan",
      "licensee": "Primevera Therapeutics, LLC",
      "licensee_country": "United States",
      "asset": "FP-025; FP-020; third-generation MMP-12 inhibitors",
      "indication": "Inflammatory and fibrotic diseases",
      "territory": "Worldwide",
      "upfront": 10000000,
      "milestones_cap": 574500000,
      "total_cap": null,
      "currency": "USD",
      "royalty_text": "tiered single-digit percentage royalties",
      "source_urls": [
        "https://www.foreseepharma.com/en/news/category/press_releases/foresee_pharmaceuticals_announces_global_licensing_agreement_for_mmp_12_inhibitors_with_primevera_therapeutics_llc?page=1"
      ],
      "source_date": "2026-01-08",
      "data_date": "2026-11-04",
      "origins": [
        "search_deals"
      ],
      "input_ids": [
        "TW-2026-004"
      ],
      "source_url": "https://www.foreseepharma.com/en/news/category/press_releases/foresee_pharmaceuticals_announces_global_licensing_agreement_for_mmp_12_inhibitors_with_primevera_therapeutics_llc?page=1"
    }
  ],
  "stats": {
    "count": 8,
    "totals_by_currency": {
      "USD": {
        "upfront": {
          "value": 10000000,
          "disclosed_count": 1
        },
        "milestones_cap": {
          "value": 574500000,
          "disclosed_count": 1
        },
        "total_cap": {
          "value": 203000000,
          "disclosed_count": 1
        }
      }
    },
    "largest_upfront_by_currency": {
      "USD": [
        "TW2026-511f8c79f916"
      ]
    },
    "licensee_countries": [
      "Australia",
      "Japan",
      "South Korea",
      "Taiwan",
      "United States"
    ],
    "company_counts": {
      "Formosa Pharmaceuticals, Inc.": 3,
      "ANXO": 1,
      "Foresee Pharmaceuticals Co., Ltd. (through Foresee Pharmaceuticals USA Inc.)": 1,
      "LUMOSA": 1,
      "TLC BioSciences Corp. / Taiwan Liposome Company": 1,
      "TaiGen Biopharmaceuticals Holdings Ltd.": 1
    }
  },
  "revision": "dec75156836d41e49b07d718f422fbd5762fe11de8bbdf11030a0b1643106361"
}